news
Dexcom OTC continuous glucose monitor approved for toddlers
Dexcom just got FDA approval for its Stelo continuous glucose monitor (CGM) for children as young as two years old. This over-the-counter device could help tackle childhood obesity, but experts are flagging concerns about its impact on young kids. The move opens up a new frontier for CGM use beyond diabetes management.
Dexcom just got FDA approval for its Stelo continuous glucose monitor (CGM) for children as young as two years old. This over-the-counter device could help tackle childhood obesity, but experts are flagging concerns about its impact on young kids. The move opens up a new frontier for CGM use beyond diabetes management.
The architecture take
So, slapping a CGM on a two-year-old for 'wellness' is officially on the table. Dexcom's OTC Stelo snagging FDA approval for toddlers sounds like a great move for data-driven parents, but it's hard not to wince a little. We're talking blood sugar monitoring potentially becoming a standard part of early childhood, not just for diagnosed conditions. While the intent might be to curb childhood obesity, the real mechanism at play here is generating a ton of data from the youngest possible users. This pushes the 'quantified self' trend further down the age ladder, which means more data for companies and potentially more anxiety for parents, not to mention pressure on kids. Watch for a flurry of apps and 'guidance' services to pop up around this, creating a whole new market for hyper-monitoring tiny humans. The next order effect? Expect to see food brands pivot their marketing even harder to appeal to parents worried about their kids' glucose spikes.